Intrexon | XON - الربح الإجمالي على المبيعات





الربح الإجمالي على المبيعات تغيير تاريخ
Agenus USD 34.2M 4.61M 2025-12
Alaunos Therapeutics USD -1.13M 1.11M 2024-09
Amgen USD 6.48B 307M 2025-09
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 256.47M 228.7M 2025-09
AstraZeneca USD 12.39B 5M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Gilead Sciences USD 6.31B 106M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Heron Therapeutics USD 29.47M 3.17M 2025-12
Incyte USD 1.39B 118.68M 2025-12
Intrexon USD -297K 167K 2024-06
Karyopharm Therapeutics USD -30.78M 1.29M 2024-12
Ligand Pharmaceuticals USD 155.28M 82.42M 2025-09
MacroGenics USD 31.11M 30.14M 2025-12
MannKind USD 78.31M 76.21M 2025-12
Merck USD 13.42B 431M 2025-09
Novartis USD 10.25B 570M 2025-12
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
Roche Holding CHF 22.09B 10.04B 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Thermo Fisher Scientific USD 4.64B 419M 2025-12
Veracyte USD 101.97M 10.69M 2025-12
Xencor USD 21M 22.61M 2025-09